Last reviewed · How we verify

Brexafemme — Competitive Intelligence Brief

Brexafemme (IBREXAFUNGERP) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triterpenoid Antifungal. Area: Infectious Disease.

marketed Triterpenoid Antifungal Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Brexafemme (IBREXAFUNGERP) — GSK.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Brexafemme TARGET IBREXAFUNGERP GSK marketed Triterpenoid Antifungal 2021-01-01
Brexafemme IBREXAFUNGERP CITRATE GSK marketed Triterpenoid Antifungal 2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triterpenoid Antifungal class)

  1. GSK · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brexafemme — Competitive Intelligence Brief. https://druglandscape.com/ci/ibrexafungerp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: